As of Aug 26
| -0.01 / -0.43%|
The 1 analysts offering 12-month price forecasts for Cancer Genetics Inc have a median target of 5.75, with a high estimate of 5.75 and a low estimate of 5.75. The median estimate represents a +147.84% increase from the last price of 2.32.
The current consensus among 1 polled investment analysts is to Buy stock in Cancer Genetics Inc. This rating has held steady since August, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.